Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neurocrine Bioscienc
(NQ:
NBIX
)
140.98
-0.67 (-0.47%)
Streaming Delayed Price
Updated: 12:57 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
Next >
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
May 04, 2024
The market rally appears to be picking up steam.
Via
Investor's Business Daily
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
May 03, 2024
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.
Via
Investor's Business Daily
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.
May 03, 2024
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Via
Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
May 02, 2024
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
May 01, 2024
Via
Benzinga
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
May 02, 2024
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.
Via
Chartmill
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
May 01, 2024
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.
Via
Investor's Business Daily
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
NBIX stock results show that Neurocrine Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
May 01, 2024
The company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia.
Via
Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.
Via
Investor's Business Daily
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
April 26, 2024
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
Via
Investor's Business Daily
3 Red-Hot Biotech Rockets Blasting Off in 2024
April 24, 2024
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in...
Via
Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
April 23, 2024
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Via
Investor's Business Daily
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.
April 11, 2024
Via
Chartmill
Where Neurocrine Biosciences Stands With Analysts
April 10, 2024
Via
Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
April 10, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
Via
Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
March 20, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
March 20, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX.
March 15, 2024
Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Via
Chartmill
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
April 05, 2024
In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
March 23, 2024
DexCom, Blackstone and Royal Caribbean head this list of five stocks.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...
Via
Benzinga
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
March 16, 2024
Three of the featured stocks are closing in on record highs.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
March 13, 2024
Via
Benzinga
NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying.
March 14, 2024
When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
March 13, 2024
Via
Benzinga
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
March 06, 2024
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.